Cell line development & upstream CMC consultancy for biologics
Z2 Biopharma Solutions supports antibody and recombinant protein programmes from host/vector and cell line strategy through media and process development, scale-up and technology transfer – helping promising science become a reproducible, scalable and manufacturable process.
- Cell Line & Media Development
- Upstream Process Development & Scale-Up
- Technology Transfer & CMC Strategy
- Due Diligence & Establishing Labs
Two decades in bioprocess development
From discovery to developable process
More than two decades of experience across academia, biotechnology and biopharmaceutical development underpin an integrated approach to cell line development, cell culture media development and upstream process development. Expertise spans monoclonal antibodies, recombinant proteins, mRNA therapeutics and emerging biotechnology platforms, covering fed-batch and perfusion development, media optimisation, process intensification, scale-up and technology transfer.
An industrial lens
Promising laboratory science viewed through an industrial development lens.
Research to manufacturing
Fundamental research, translational science, global CDMO and commercial bioprocessing.
Integrated cell line, media & upstream development
Cell Line Development
Host, vector and selection-system strategy, clone screening and selection, stability and clonality – planned for the molecule and its CMC path.
Cell Culture Media Development
Media and feed optimisation, raw-material strategy and metabolic interpretation to lift growth, titre and consistency.
Upstream Process Development
Shake-flask and bioreactor development, fed-batch and perfusion, seeding and feeding strategies and process intensification.
Process Characterisation & Optimisation
QbD, DoE, critical process parameters, robustness and qualified scale-down models.
Scale-Up & Technology Transfer
Transfer strategy, CMC and process-transfer packages, site gap analysis, comparability and receiving-site readiness.
CMC & Development Strategy
CMC planning, IND/BLA documentation support, technical due diligence and investment readiness.
AI/ML & Bioprocess Data Analytics
Design of experiments and multivariate analysis, with specialist modelling partners where a programme needs them.
Establishing Biologics Labs
Laboratory set-up, workflows, SOPs, qualification, biosafety/GMO compliance and technical team mentoring.
Identify issues and gaps earlier
Unstable clones, long CMC timelines and scarce talent raise the cost of early mistakes. Each risk needs tackling at source, by someone who has seen where these early decisions lead.
8–63%
Cell line: stability-led clone selection
of recombinant CHO cell lines showed unstable production across published studies.1
~35%
Upstream: predictive scale-down models
lower peak antibody titre after extended passaging, in one CHO stability study.2
18 months
CMC path: a CMC plan set up front
typical CMC work to reach IND for a monoclonal antibody, costing about $7M.3
36%
People: senior PD on demand
Process development has topped the list of hard-to-fill roles in biomanufacturing for over a decade — 38.5% of facilities reported difficulty hiring upstream PD staff in 2015,4 and 36% still cannot hire process development staff in 2025.5
1 US Patent 10,913,984 (review of published DHFR/GS CHO stability data). 2 Exploring CHO cell stability during prolonged passaging via explainable AI-driven flux balance analysis, PMC12992790. 3 Contract Pharma, CMC Activities for Development of MAbs, 2024. 4 BioProcess International. Hiring and Staffing in Biopharmaceutical Manufacturing: Five-Year Trends Indicate Difficulty in Filling Positions, Eric S. Langer, January 2016. 5 BioPlan Associates, 22nd Annual Report and Survey of Biopharmaceutical Manufacturing, 2025. Read the full briefing
Accelerating development through science, data & AI
Smarter experiments, better decisions
Bioprocess development is increasingly data-rich, multidimensional and predictive. Z2 combines biological and process-development understanding with an expanding capability in AI, machine learning, multivariate analysis and advanced data analytics.
- Media optimisation & predictive modelling
- Critical process relationships
Beyond "running more experiments"
Better-designed studies and more from data already gathered cut development time and technical risk together.
- DoE, multivariate analysis and scale-down models
- Modelling scoped and directed by Z2, built by specialist partners
Science and industry, connected
Z2 connects scientific innovation with industrial bioprocess thinking – helping research become translatable, processes become scalable, and development organisations become stronger.
Supporting programmes from research to manufacturing
From early-stage concepts and proof-of-concept studies through active bioprocess development towards manufacturing readiness.
Biotech & Start-ups
A senior CMC lead without a permanent hire; CLD and CDMO choices set up right.
Learn MoreEmerging CDMOs
CLD and upstream platforms, laboratories, SOPs and GMO compliance built for growth.
Learn MoreEstablished Biopharma
Senior cell line and upstream expertise, independent programme review and extra capacity at critical milestones.
Learn MoreUniversities, Academia & Research Organisations
Research processes made scalable: translational strategy, CMC input for spin-outs and grants, labs and trained teams.
Learn MoreInvestors & Strategic Partners
Independent CMC and technical due diligence – red flags found before you commit.
Learn MoreIndustry-relevant training for bioprocess scientists
Practical training drawn from industrial cell line, media and upstream development – for academic groups, start-ups and growing CDMO teams.
Cell Culture & Upstream PD
Fed-batch and perfusion, media and feeds, bioreactor operation and troubleshooting.
DoE & QbD
Experimental design, critical process parameters and scale-down models in practice.
Establishing biologics infrastructure
Facility and equipment selection, qualification, workflows, SOPs and GMO containment.
Let's talk about your programme
Whether you are designing a CLD programme, stuck on an upstream process, preparing for technology transfer, or assessing a biologics asset before you commit.
Email Z2